Discontinuation of anticoagulant therapy for a month in a patient with HeartMate III continuous-flow left ventricular assist device without thromboembolic events

Publication date: July 2018Source: Journal of the Saudi Heart Association, Volume 30, Issue 3Author(s): Abdelfatah Elasfar, Kafaf Jalali, Mohamed Hussein, Ibraheem AlHarbi, Osama AmoudiAbstractThe recommended anticoagulation regimen for continuous-flow left ventricular assist device (LVAD) systems is warfarin and aspirin with a targeted international normalized ratio (INR) of 2.0–3.0. Our patient is a 58-year-old male who underwent surgical HeartMate III continuous-flow LVAD implantation 3 months ago outside the country. The patient mistakenly stopped taking warfarin for 1 month prior to presenting to our center for a routine visit. Luckily, the patient was doing very well without any complication despite the fact that his INR was 1.0.
Source: Journal of the Saudi Heart Association - Category: Cardiology Source Type: research